
---
title: '默沙东新冠口服药获英国监管机构批准'
categories: 
 - 新媒体
 - cnBeta
 - 最新
headimg: 'https://static.cnbetacdn.com/article/2021/1002/9205f4190213848.jpg'
author: cnBeta
comments: false
date: Thu, 04 Nov 2021 11:51:30 GMT
thumbnail: 'https://static.cnbetacdn.com/article/2021/1002/9205f4190213848.jpg'
---

<div>   
据报道，英国药品和保健品监管机构（MHRA）已批准由默沙东（MRK.US）和Ridgeback Biotherapeutics研发的新冠口服药molnupiravir。根据默沙东和Ridgeback公司的一份声明，MHRA已批准了其新冠口服药molnupiravir用于治疗轻至中度新冠患者。<br>
 <p><a href="https://static.cnbetacdn.com/article/2021/1002/9205f4190213848.jpg" target="_blank"><img src="https://static.cnbetacdn.com/article/2021/1002/9205f4190213848.jpg" referrerpolicy="no-referrer"></a><a href="https://static.cnbetacdn.com/thumb/article/2020/0527/57e58f489c97569.png" target="_blank"><img src="https://static.cnbetacdn.com/thumb/article/2020/0527/57e58f489c97569.png" referrerpolicy="no-referrer"></a></p><p>据悉，此前在一项涉及轻至中度新冠患者的3期临床试验的中期分析中，默沙东的药物molnupiravir可将住院或死亡风险降低约50%。</p><p>截至发稿，默沙东盘前涨1.67%，报90.16美元。</p><div class="article-relation"><p><strong>相关文章:</strong></p><p><a href="https://www.cnbeta.com/articles/tech/1194715.htm" target="_blank">EMA启动对默沙东新冠口服药的滚动审评</a></p><p><a href="https://www.cnbeta.com/articles/tech/1197361.htm" target="_blank">默沙东预计到2022年底其抗新冠口服药物销售额将达到70亿美元</a></p></div>   
</div>
            